白蛋白结合型紫杉醇联合替吉奥治疗晚期胰腺癌的研究进展  

Progress in the treatment of advanced pancreatic cancer with albumin-bound paclitaxel combined with S-1

作　　者：吴莉 郑桐森[1] WU Li;ZHENG Tongsen(Harbin Medical University Cancer Hospital,Heilongjiang Harbin 150081,Ghina.)

机构地区：[1]哈尔滨医科大学附属肿瘤医院,黑龙江哈尔滨150081

出　　处：《现代肿瘤医学》2022年第9期1706-1709,共4页Journal of Modern Oncology

摘　　要：胰腺癌早期症状隐匿,恶性程度高,是消化系统常见的恶性肿瘤之一。外科手术是延长胰腺癌患者生存期的最佳选择,但只有15%~20%的胰腺癌患者能接受手术治疗。其余患者因局部晚期或全身转移,只能进行以内科治疗为主的综合治疗。目前晚期胰腺癌患者的首选治疗方式是以吉西他滨为基础的化疗,但仅使晚期胰腺癌患者的平均生存期延长为5.5~7个月,疗效有限。近几年,多项研究证实白蛋白结合型紫杉醇联合替吉奥治疗晚期胰腺癌可以提高患者的PFS和OS(分别为6.2个月和13.6个月)。治疗过程中最常出现的不良反应是中性粒细胞减少,但未出现因不良反应而停止治疗或死亡的现象。为晚期胰腺癌患者的治疗带来了新希望。本文将总结白蛋白结合型紫杉醇联合替吉奥在治疗晚期胰腺癌中的相关研究。Pancreatic cancer is one of the most common malignancies in the digestive system.Surgery is the best option to extend the survival of pancreatic cancer patients,but only 15 to 20 percent of pancreatic cancer patients can receive surgical treatment.The rest of the patients due to local late or systemic metastasis,can only be given medical treament-based comprehensive treament.Currently,gemcitabine-based chemotherapy is the preferred treatment for patients with advanced pancreatic cancer,but it only extends the average survival time of patients with advanced pancreatic cancer to 5.5 to 7 months,with limited efficacy.In recent years,several studies have demonstrated that albumin-bound binding paclitaxel combined with S-1 can improve PFS and OS in patients with advanced pancreatic cancer(6.2 and 13.6 months,respectively).The most common adverse reaction during treatment was neutropenia,but there was no adverse reaction that led to the cessation of treatment or death.It brings new hope for the treatment of advanced pancreatic cancer patients.This article will summarize the research on the treatment of advanced pancreatic cancer with albumin-bound paclitaxel combined with S-1.

关 键 词：晚期胰腺癌 白蛋白结合型紫杉醇 替吉奥 疗效 安全性 

分 类 号：R735.9[医药卫生—肿瘤]